Standards for providing safe acute ischaemic stroke thrombectomy services (September 2015).

Stroke is the third leading cause of death and the leading cause of disability in Europe. The management of acute ischaemic stroke is a major healthcare challenge but improving outcomes for acute stroke patients offers major benefits to patients, healthcare systems and society as a whole. Conscious sedation Emergency Department General anaesthesia General Medical Council Intra-arterial Intra-arterial thrombectomy Third interventional management of stroke trial Interventional Neuroradiologist Intravenous Intravenous thrombolysis modified Rankin score National Institute for Health & Clinical Excellence National Institutes for Health stroke scale randomised controlled trial symptomatic intracerebral haemorrhage Safe implementation of treatments in stroke tissue plasminogen activator Commentary on: Implementing mechanical thrombectomy for acute ischaemic stroke in the UKClinical RadiologyVol. 72Issue 2PreviewTreatment and prevention of stroke is a major individual and healthcare problem throughout the world, and there is no doubting the importance of treatment developments. The publication of the recent randomised trials1–5 demonstrating the benefit of mechanical thrombectomy (MT) is indeed a welcome piece of evidence in improving the acute treatment of so-called “large artery occlusion” (LAO) ischaemic stroke. Full-Text PDF Commentary on: Implementing mechanical thrombectomy for acute ischaemic stroke in the UKClinical RadiologyVol. 72Issue 2PreviewStroke is the third leading cause of death and the leading cause of disability in the developed world.1 The treatment approach for acute ischaemic stroke is straightforward: restore blood flow as soon as possible and as safely and completely as possible.2 Approximately half of patients with anterior circulation ischaemic stroke will have a large artery occlusion (LAO),3,4 which carries the worst prognosis for recovery. The results of intravenous thrombolysis (IVT) using tissue plasminogen activator (Alteplase), delivered within 4.5 hours, in LAO stroke are disappointing with recanalisation rates <10% for the internal carotid artery and <33% for the middle cerebral artery. Full-Text PDF